View source for DIABETES MELLITUS-NEPHROPATHY MANAGEMENT

===== [[Summary Article|'''SUMMARY''']] =====
<i>ACE INHIBITORS/ANGIOTENSIN RECEPTOR BLOCKERS</i>
<br/>1. Renoprotection in T2DM offered by ACEi &amp; ARBs was demonstrated in RENAAL &amp; IDNT studies.
<br/>2. These work by reducing intraglomerular pressure, by reducing efferent arteriolar tone. 
<br/>
<br/><i>SGLT2 INHIBITION</i>
<br/>3. The CREDENCE study delay in progress in patients with established diabetic nephropathy who were treated with Canagliflozin<ref>Perkovic, V., de Zeeuw, D., Mahaffey, K., Fulcher, G., Erondu, N., Shaw, W., Barrett, T., Weidner-Wells, M., Deng, H., Matthews, D. and Neal, B., 2018. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. <i>The Lancet Diabetes &amp; Endocrinology</i>, 6(9), pp.691-704.</ref>.


==Reference(s)==
<references />
<br/>Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. [https://amzn.to/3YHrI6K Get it on Amazon.]
<br/>Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. [https://amzn.to/3k7WSW0 Get it on Amazon.]
<br/>Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
<br/>Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].

[[Category:Diabetes Mellitus]]
[[Category:Endocrinology]]
[[Category:Medicine]]